Semaglutide Clinical Data The STEP trial program represents the most comprehensive clinical evaluation of any GLP-1 receptor agonist for weight management: STEP 1: 14.9% mean body weight loss over 68 weeks (Wilding et al., NEJM , 2021) STEP 3: 16.0% with intensive behavioral therapy over 68 weeks STEP 5: Sustained 15.2% weight loss maintained at 104 weeks with continued treatment SELECT trial: Demonstrated 20% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in addition to weight loss, establishing cardiovascular benefit (Lincoff et al., NEJM , 2023) The SELECT trial result is particularly significant because it demonstrated that semaglutide provides cardiovascular protection independent of weight loss, a benefit that has not been established for tesofensine
Neuroprotective and anti-apoptotic effects of liraglutide on SH-SY5Y cells exposed to methylglyoxal stress
Everything You Need to Know Most patients start noticing reduced appetite within the first week, with visible weight loss beginning around 2-4 weeks
Pharmacognosy Magaz 11(41):96 Dantas TL, Alonso Buriti FC, Florentino ER (2021) Okra ( Abelmoschus esculentus L.) as a potential functional food source of mucilage and bioactive compounds with technological applications and health benefits
